Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug

Kelun Pharmaceutical’s Sacituzumab Tirumotecan Receives Priority Review for NSCLC Treatment

Fineline Cube Aug 16, 2024

Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) has announced that its drug sacituzumab tirumotecan (SKB264/MK-2870)...

Company Deals

Huadong Medicine Secures Licensing Deal with IMBiologics for Autoimmune Drug Candidates

Fineline Cube Aug 16, 2024

Huadong Medicine Co., Ltd. (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing...

Company Drug

Lykos Therapeutics Faces Setback as FDA Rejects Midomafetamine for PTSD Treatment

Fineline Cube Aug 16, 2024

Lykos Therapeutics, a U.S.-based biotech firm, has expressed concern over the impact of the FDA’s...

Company Drug

Chugai Seeks Approval for Elevidys Gene Therapy in Japan, Targeting Duchenne Muscular Dystrophy

Fineline Cube Aug 16, 2024

Chugai Pharmaceutical Co., Ltd. (TYO: 4519), a subsidiary of Roche, has submitted a product approval...

Company Drug

Staidson Launches Phase Ia Trial for STSP-0902 Injection in Oligoasthenozoospermia

Fineline Cube Aug 16, 2024

Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) has announced that it has received approval from...

Company Drug

Jiangsu Hengrui Secures NMPA Approval for Clinical Trials of SHR-2106 in Primary Sjögren’s Syndrome

Fineline Cube Aug 16, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical trial...

Company Medical Device

Lepu Scientech Secures NMPA Approval for MemoSORB Biodegradable Atrial Septal Defect Occluder

Fineline Cube Aug 16, 2024

Lepu Scientech Medical Technology (Shanghai) Co., Ltd. (HKG: 2291) has announced that it has received...

Company Medical Device

Sino Medical Secures Moroccan Approvals for NC Rockstar Catheter and HT Supreme Stent System

Fineline Cube Aug 16, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), a prominent player in China’s medical device sector,...

Company Drug

Vimgreen Pharma Launches Phase II Trial for A2AR Antagonist VG081821AC in Parkinson’s Disease

Fineline Cube Aug 16, 2024

Zhejiang-based Vimgreen Pharma has announced the launch of a Phase II clinical trial for its...

Company Drug

Gilead Secures FDA Accelerated Approval for Livdelzi in Liver Disease Treatment

Fineline Cube Aug 15, 2024

Gilead Sciences Inc. (NASDAQ: GILD) has received accelerated approval from the U.S. FDA for its...

Company Drug

Astellas Pharma Secures UK Approval for First-in-Class Gastric Cancer Therapy Vyloy

Fineline Cube Aug 15, 2024

Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has secured market approval in the...

Company

GSK’s Ma Zheng to Depart as Head of Communication and Government Affairs in China

Fineline Cube Aug 15, 2024

Ma Zheng, the head of communication and government affairs for GSK plc (NYSE: GSK) in...

Company Deals Medical Device

Shanghai Sanyou Medical to Acquire Full Control of SMTP Technology for RMB 415.7 Million

Fineline Cube Aug 15, 2024

Shanghai Sanyou Medical Co., Ltd. (SHA: 688085), based in China, is set to acquire the...

Company Deals Drug

Shandong Buchang Pharmaceuticals Partners with Lancet for BC001 Licensing in Eurasia

Fineline Cube Aug 15, 2024

Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858), based in China, has announced plans to enter...

Company Drug

Biogen and Eisai Secure UAE Approval for Alzheimer’s Therapy Leqembi

Fineline Cube Aug 15, 2024

Biogen Inc. (NASDAQ: BIIB), based in the U.S., and Japan’s Eisai Co., Ltd. have announced...

Policy / Regulatory

Shaanxi Leads New Provincial Alliance for Volume-Based Procurement of Medical Products

Fineline Cube Aug 15, 2024

The Shaanxi Public Resources Trading Center has announced the formation of a provincial alliance for...

Company Drug

CStone to Manufacture Gavreto Locally Following NMPA Approval, Expanding Market Presence

Fineline Cube Aug 15, 2024

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has received approval from the National Medical...

Company Medical Device

China’s Sansure Biotech Launches Approved Kit for Alzheimer’s and Cardiovascular Risk Assessment

Fineline Cube Aug 15, 2024

Sansure Biotech Inc. (SHA: 688289), a China-based leader in molecular diagnostics, has secured marketing approval...

Company Drug

Qilu Pharmaceutical Gains Approval for Generic Dasatinib, Expanding CML Treatment Options in China

Fineline Cube Aug 14, 2024

Qilu Pharmaceutical, based in China, has received marketing approval for its generic version of Bristol-Myers...

Company

Eli Lilly Unveils $700 Million R&D Center in Boston to Boost Genetic Medicine Efforts

Fineline Cube Aug 14, 2024

Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport...

Posts pagination

1 … 366 367 368 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.